Peter Beck's Neutron Rocket Could Slip to 2027. Here's How Much the Delay Actually Matters.

Rocket Lab said a hydrostatic pressure test failure in January ruptured the Stage 1 main propellant tank, pushing its Neutron launch outlook from late-2026 to potentially 2027 (while still targeting rollout to the pad in Q4 2024). CEO Peter Beck warned the window for an end-year launch is narrowing and emphasized a long-term “risk trading” plan focused on readiness for flight operations through flight 10. The company expects adjusted EBITDA to turn positive once Neutron begins flying, but the delay is a near-term setback for investor sentiment.

Analysis

The core impact is not the delayed launch itself; it is the extension of the cash-burning proof period. RKLB was being valued on a near-term re-rating from a new launch class, so pushing that back roughly a year keeps the company in the pre-inflection bucket longer and raises the odds that equity funding, not operating leverage, bridges the gap. That is bearish for multiple expansion because investors now have to discount a longer runway before the Neutron option becomes monetizable.

Second-order, this is a relative winner for incumbents with existing lift capacity and for defense/aerospace contractors that can absorb demand that would have been bid by RKLB. Customers with mission timelines will not wait for a cleaner launch narrative, so the delay likely shifts contracting power back toward established providers and reduces pressure on pricing in the medium-lift niche. For space-theme vehicles such as SPCX, the issue is sentiment beta: a high-profile slip can compress the whole basket even if underlying holdings are unaffected.

Contrarian view: the market may be over-penalizing a schedule slip that is economically less important than execution quality. If management truly prioritizes repeatability, a slower first flight could reduce failure risk and make the eventual commercialization curve steeper; the thesis only breaks if the delay drifts beyond 2027, capex/dilution steps up, or ground-test cadence starts slipping again. Near term, the stock should trade on test milestones and financing risk, not on Neutron revenue that still sits well outside the P&L.

Key Decisions for Investors

• Short RKLB on rallies or buy 3-6 month put spreads into the next test cadence; base case is further multiple compression as the 2027 start line becomes the new anchor. Falsifier: on-time pad rollout plus clean ground tests with no change to 2027.
• Use a relative-value trade: long defense/aerospace cash-flow exposure, short RKLB, to isolate execution risk from sector beta. Best if you want to fade launch optionality without taking a broad space-market view.
• If holding SPCX, hedge with RKLB puts rather than selling the basket outright; the ETF can absorb sentiment shock even when the thesis is company-specific.
• Add an alert on dilution/capex commentary and any change to the Neutron timetable; if management pushes beyond 2027 or hints at incremental financing, increase bearish exposure.